Medicare could’ve saved $3.6 billion by buying drugs at same prices as Mark Cuban’s online pharmacy, according to a new study

22 June 2022 - Medicare’s drug program could have saved up to $3.6 billion in 2020 by mirroring the pricing ...

Read more →

NICE recommends new targeted treatment for early breast cancer

16 June 2022 - NICE has provisionally approved a new treatment for early breast cancer that it says will benefit ...

Read more →

Why won’t the FDA let doctors prescribe fluvoxamine for COVID?

30 May 2022 - Trials show it keeps patients from getting sicker, but the agency won’t approve its emergency use. ...

Read more →

Medicare premium increase from Alzheimer’s drug to be lowered next year

27 May 2022 - Health and Human Services Secretary Xavier Becerra announced on Friday that Medicare premiums would be adjusted ...

Read more →

Medicare spending on drugs with accelerated approval

24 May 2022 - The U.S. FDA provides accelerated approval to drugs on the basis of surrogate end points deemed to ...

Read more →

CMS unveils more user friendly Medicare website

18 May 2022 - New Medicare.gov will incorporate public feedback and make it easier to compare, choose, and understand Medicare ...

Read more →

Federal investigators find Medicare Advantage plans too often deny, delay needed care

10 May 2022 - Medicare Advantage plans that provide health insurance coverage to millions of US seniors deny some medically ...

Read more →

The Center for Medicare and Medicaid Innovation - toward value based care

9 May 2022 - Before the enactment of the Patient Protection and Affordable Care Act in 2010, experimentation with Medicare or ...

Read more →

Aadi Bioscience announces unique permanent J code issued for Fyarro from Centers for Medicare and Medicaid Services

4 May 2022 - Effective 1 July J code will enable a streamlined reimbursement process for Fyarro. ...

Read more →

Your money or your life - the high cost of cancer drugs under Medicare Part D

4 May 2022 - The financial burden associated with orally administered anti-cancer drugs can be overwhelming for Medicare beneficiaries.  ...

Read more →

Medicare’s decision not to fund Aduhelm changes landscape for US pharma industry

19 April 2022 - The decision by the agency responsible for Medicare to restrict coverage of Biogen’s Alzheimer’s drug aducanumab ...

Read more →

Prioritising reference products over biosimilars led to millions of missed savings for Part D

20 April 2022 - Medicare Part D plans missed out on between $84 million and $143 million in savings by ...

Read more →

CMS finalises Medicare coverage policy for monoclonal antibodies directed against amyloid for the treatment of Alzheimer’s disease

7 April 2022 - Today, the CMS released a national policy for coverage of aducanumab (Aduhelm) and any future monoclonal antibodies ...

Read more →

Inside a campaign to get Medicare coverage for a new Alzheimer’s drug

6 April 2022 - The Alzheimer’s Association has pushed relentlessly to get broad access to Aduhelm, despite safety risks and ...

Read more →

Medicare bulk billing rates surge across our health system

6 March 2022 - Essential medical care is more affordable than ever before with the number of Australians receiving essential medical ...

Read more →